Fig. 2From: Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumorsCumulative overall survival rates according to incidence of immune-related adverse events (irAEs). Overall survival rate was significantly higher in patients who developed irAEs during immune checkpoint inhibitor treatmentBack to article page